Erythrodermic Psoriasis Treated with Golimumab: A Case Report.
- Author:
Won Ku LEE
1
;
Gun Wook KIM
;
Hyun Ho CHO
;
Won Jeong KIM
;
Je Ho MUN
;
Margaret SONG
;
Hoon Soo KIM
;
Hyun Chang KO
;
Moon Bum KIM
;
Byung Soo KIM
Author Information
- Publication Type:Case Report
- Keywords: Biological products; Erythrodermic psoriasis; Golimumab; Psoriasis; Psoriatic arthritis
- MeSH: Adult; Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Products; Cyclosporine; Dermatitis, Exfoliative; Humans; Methotrexate; Phototherapy; Psoriasis*; Skin; Spondylitis, Ankylosing; Steroids
- From:Annals of Dermatology 2015;27(4):446-449
- CountryRepublic of Korea
- Language:English
- Abstract: Erythrodermic psoriasis (EP) is a very severe variant of psoriasis whose management poses a challenge to physicians, as currently available therapies often provide unsatisfactory results. Many biologics have been used to treat chronic plaque psoriasis, the most common form of psoriasis; however, their effectiveness for EP is poorly understood. A recently developed biologic, golimumab, has been extensively studied for the treatment of moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, active ankylosing spondylitis, and chronic plaque psoriasis. However, no clinical trials have been performed for EP. Here, we report the case of a 32-year-old man who presented with severe psoriasis that previously failed to respond satisfactorily to methotrexate, cyclosporine, retinoid, narrow-band ultraviolet B phototherapy, and topical agents (i.e., steroids and calcipotriol). Skin lesions worsened progressively and developed into erythroderma. Psoriatic arthritis was also detected. Conventional therapies lacked efficacy. Therefore, we administered golimumab 50 mg. The skin lesions improved significantly according to the Psoriasis Area and Severity Index score after the first administration; lesions improved further throughout the treatment course. Although additional studies are required to fully evaluate the efficacy and safety of golimumab, this agent may be an alternative treatment strategy for some patients with recalcitrant EP.
